Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Cash from Investing Activities (2021 - 2025)

Amylyx Pharmaceuticals has reported Cash from Investing Activities over the past 5 years, most recently at $29.5 million for Q4 2025.

  • Quarterly results put Cash from Investing Activities at $29.5 million for Q4 2025, down 54.65% from a year ago — trailing twelve months through Dec 2025 was $14.0 million (down 81.44% YoY), and the annual figure for FY2025 was $14.0 million, down 81.44%.
  • Cash from Investing Activities for Q4 2025 was $29.5 million at Amylyx Pharmaceuticals, up from $5.2 million in the prior quarter.
  • Over the last five years, Cash from Investing Activities for AMLX hit a ceiling of $123.2 million in Q2 2023 and a floor of -$228.2 million in Q4 2022.
  • Median Cash from Investing Activities over the past 5 years was $4.5 million (2022), compared with a mean of -$5.5 million.
  • Biggest five-year swings in Cash from Investing Activities: tumbled 709264.29% in 2022 and later skyrocketed 2661.59% in 2023.
  • Amylyx Pharmaceuticals' Cash from Investing Activities stood at $2.8 million in 2021, then crashed by 8208.74% to -$228.2 million in 2022, then soared by 109.17% to $20.9 million in 2023, then skyrocketed by 210.54% to $65.0 million in 2024, then tumbled by 54.65% to $29.5 million in 2025.
  • The last three reported values for Cash from Investing Activities were $29.5 million (Q4 2025), $5.2 million (Q3 2025), and $23.0 million (Q2 2025) per Business Quant data.